Product Description

NOBIVAC® 3-Rabies CA has been shown to be effective for the vaccination of healthy dogs and cats 12 weeks of age or older against rabies. Duration of immunity of at least 3 years in dogs and cats has been demonstrated after repeat dose.
-Proven to be uniformly safe in experimental tests, with no significant adverse reactions in extensive clinical trials.1
-Approved for Sale in California
-Subcutaneous 1 mL injection for cats
-Subcutaneous or intramuscular 1 mL injection for dogs
-Administer a single dose at 12 weeks of age or older in healthy cats and dogs; repeat dose should be administered 1 year later. Revaccinate every 3 years with a single dose
-Available in two presentations: 50 x 1 mL, and 5 x 10 mL vials

SAFETY AND EFFICACY
Because Nobivac 3-Rabies vaccine is produced on an established cell line, it has safety advantages over inactivated brain-origin rabies vaccines. Tissue origin vaccines contain extraneous protein in addition to rabies antigen that can lead to autoimmune disease.

The established cell line used in Nobivac 3-Rabies has been extensively tested for freedom from contaminating agents. In addition, use of an established cell line yields a vaccine of consistent potency from serial to serial. Nobivac 3-Rabies has proven to be uniformly safe in experimental tests and no significant adverse reactions were reported in extensive clinical trials of the vaccine.

Duration of immunity studies, conducted in accordance with federal regulation and under U.S. Department of Agriculture direction, demonstrated that a 1 mL dose met federal guidelines for protection of dogs and cats against virulent challenge administered 3 years after vaccination. Cattle and sheep were likewise protected one year after receiving a 2 mL dose of Nobivac 3-Rabies.